Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,380 Mln
P/E Ratio
45.4
P/B Ratio
0
Industry P/E
--
Debt to Equity
-0.61
ROE
0 %
ROCE
52.5 %
Div. Yield
0 %
Book Value
--
EPS
0.1
CFO
$-458.84 Mln
EBITDA
$-663.16 Mln
Net Profit
$-978.34 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
MannKind Corp (MNKD)
| -28.30 | -11.69 | -25.28 | 12.17 | 11.45 | 29.41 | -15.38 |
|
BSE Sensex*
| 2.14 | 3.92 | 4.44 | 8.38 | 11.80 | 20.19 | 11.16 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
MannKind Corp (MNKD)
| 75.83 | -30.93 | 20.59 | 39.62 | 142.64 | 21.70 | -54.11 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled... insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. Address: 1 Casper Street, Danbury, CT, United States, 06810 Read more
CEO & Director
Dr. Michael E. Castagna Pharm.D.
CEO & Director
Dr. Michael E. Castagna Pharm.D.
Headquarters
Danbury, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of MannKind Corp (MNKD) stood at $ 394 Mln as on 31-Dec-24
The share price of MannKind Corp (MNKD) is $4.61 (NASDAQ) as of 23-Apr-2025 16:00 EDT. MannKind Corp (MNKD) has given a return of 11.45% in the last 3 years.
MannKind Corp (MNKD) has a market capitalisation of $ 1,380 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of MannKind Corp (MNKD) is 45.40 times as on 21-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the MannKind Corp (MNKD) and enter the required number of quantities and click on buy to purchase the shares of MannKind Corp (MNKD).
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. Address: 1 Casper Street, Danbury, CT, United States, 06810
The CEO & director of Dr. Michael E. Castagna Pharm.D.. is MannKind Corp (MNKD), and CFO & Sr. VP is Dr. Michael E. Castagna Pharm.D..
There is no promoter pledging in MannKind Corp (MNKD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| MannKind Corp (MNKD) | Ratios |
|---|---|
|
Return on equity(%)
|
-16.98
|
|
Operating margin(%)
|
23.99
|
|
Net Margin(%)
|
9.66
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of MannKind Corp (MNKD) was $0 Mln.
$0.03
(
